Inc. (NASDAQ: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced the presentation of favorable clinical
findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II
trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a
CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part
of a broader collaboration between the companies. The study results were
reported in an oral abstract session at the American Society of Clinical
Oncology (ASCO) 50th Annual Meeting being held in Chicago,
IL; they were also selected for Best of ASCO (abstract #8506).
In the data presented today, study investigators reported achievement of
proof of concept, with 43.9% objective response rate (ORR) for the per
protocol population (patients with relapsed or relapsed/refractory
disease). The primary objective of the study was to assess whether
single agent SAR3419 could achieve an ORR of at least 20% in this
patient population using Cheson 2007 criteria. Additionally, objective
responses were reported among the patients enrolled with primary
refractory disease - cancer that had not responded to first-line
treatment - with a 21.4% ORR.
"SAR3419 demonstrated promising activity against previously treated
DLBCL, including disease that had not responded to first-line
treatment," commented Daniel Junius, president and CEO of ImmunoGen. "We
believe the unique profile of SAR3419 can make an important difference
for patients with DLBCL, and potentially for other types of B-cell
malignancies. These data also add to the growing body of favorable
findings with ADCs using our technology."
The STARLYTE trial is evaluating the efficacy and safety of SAR3419 used
as a single agent to treat relapsed or relapsed/refractory CD19-positive
DLBCL. Patients received SAR3419 at 55 mg/m2 weekly for
four weeks and then every other week until disease progression or
discontinuation. Of the patients enrolled in the trial, 55 were
evaluable for efficacy and 61 were evaluable for safety.
The 41 per protocol patients included 26 patients with relapsed but not
refractory disease and 15 patients with disease refractory to their last
treatment. Among these patients:
The 55 efficacy evaluable patients also included 14 individuals with
primary refractory disease. Among these patients, the ORR was 21.4%,
with 35.7% having stable disease or better. The objective responses
reported included 1 CR as well as 2 PRs.
The investigators reported that SAR3419 was found to have a favorable
safety profile, with few treatment-related grade 3/4 adverse events
(AEs) or serious AEs reported. No grade 3 or 4 peripheral neuropathy or
ocular events were observed; any ocular events were low grade (1 or 2),
manageable and reversible. Moderate hematological toxicities were
reported including anemia, thrombocytopenia and neutropenia.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen
has three wholly owned product candidates in clinical testing with
additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including SAR3419, including risks related to preclinical and clinical
studies, their timings and results. A review of these risks can be found
in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June
30, 2013 and other reports filed with the Securities and Exchange
[ Back To NFVZone's Homepage ]